Clinical Characterization of Patients With <scp>5q</scp> Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross‐Sectional Observational Study

Spinal muscular atrophy (SMA), linked to chromosome 5q, is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. It is classified into subtypes based on age at onset and the highest motor milestone achieved. This cross-sectional observational study aimed to describe the clinical profile of patients with types 2 and 3 SMA followed within the Brazilian Public Health System (SUS). Clinical data from patients with types 2 and 3 SMA followed at nine national reference centers (2020-2021) were analyzed. A total of 155 patients were included: 76 with type 2 and 79 with type 3 SMA. Disease duration was longer in type 3 patients. Time from symptom onset to genetic confirmation was also longer in this group. Functional impairment was observed in both subtypes. Type 2 patients had lower HFMSE scores overall, though higher scores were seen among those on disease-modifying therapies. In type 3, earlier symptom onset and longer disease duration were associated with worse motor outcomes. HFMSE scores varied with treatment use and disease duration. Findings reveal the clinical heterogeneity of SMA and emphasize the impact of diagnostic delays and disease duration on function. Early diagnosis and ongoing multidisciplinary care are crucial.

Authors

Institutions

Publication Details

Journal
Clinical Genetics
Published
2026-05-08
DOI
https://doi.org/10.1111/cge.70176
Primary Topic
Neurogenetic and Muscular Disorders Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Characterization of Patients With 5q Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross‐Sectional Observational Study

Graziela Jorge Polido, Ronaldo V P Soares, Gisele Sampaio Silva, Paulo Victor Sgobbi de Souza et al.
Clinical Genetics
Neurogenetic and Muscular Disorders Research
article

Clinical Characterization of Patients With 5q Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross‐Sectional Observational Study

Graziela Jorge Polido, Ronaldo V P Soares, Gisele Sampaio Silva, Paulo Victor Sgobbi de Souza, Raquel Tavares Boy da Silva, André Luíz Santos Pessoa, Jomênica de Bortoli Livramento, Denison Pedrosa, Frederico Monfardini, Viviane Aparecida Rodrigues Sant’Anna, Pereira Mde B, Luciana Pereira Almeida de Piano, Luiz Vicente Rizzo, Jonas Alex Morales Saute, Alexandra Prufer de Queiroz Campos Araújo, Adriana Banzzatto Ortega, Elice C. Batista, Bruna dos Santos Sampaio, Camila Santos Nascimento Albuquerque, Flávia Duarte, Gustavo Prado dos Santos, Juliana Gurgel Giannetti, O Berwanger, Acary Souza Bulle Oliveira, Vanessa Teich, Marcondes Cavalcante França Junior, Diogo Fagundes Moia, João Brainer Clares de Andrade, Henrique Andrade R. Fonseca, Mário Fritsch Toros Neves, Fernando Galan Júnior, Edmar Zanoteli
article en

Abstract

Spinal muscular atrophy (SMA), linked to chromosome 5q, is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. It is classified into subtypes based on age at onset and the highest motor milestone achieved. This cross-sectional observational study aimed to describe the clinical profile of patients with types 2 and 3 SMA followed within the Brazilian Public Health System (SUS). Clinical data from patients with types 2 and 3 SMA followed at nine national reference centers (2020-2021) were analyzed. A total of 155 patients were included: 76 with type 2 and 79 with type 3 SMA. Disease duration was longer in type 3 patients. Time from symptom onset to genetic confirmation was also longer in this group. Functional impairment was observed in both subtypes. Type 2 patients had lower HFMSE scores overall, though higher scores were seen among those on disease-modifying therapies. In type 3, earlier symptom onset and longer disease duration were associated with worse motor outcomes. HFMSE scores varied with treatment use and disease duration. Findings reveal the clinical heterogeneity of SMA and emphasize the impact of diagnostic delays and disease duration on function. Early diagnosis and ongoing multidisciplinary care are crucial.

Clinical Genetics
Universidade Federal de Minas Gerais (BR), Universidade Federal do Rio de Janeiro (BR), Universidade Federal do Rio Grande do Sul (BR), Universidade de São Paulo (BR), Universidade Estadual de Campinas (UNICAMP) (BR), The George Institute for Global Health (GB), Hospital Israelita Albert Einstein (BR), Hospital de Clínicas de Porto Alegre (BR), Hospital Universitário Pedro Ernesto (BR), Hospital Erasto Gaertner (BR), Hospital Infantil Albert Sabin (BR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Imperial College London (GB), Universidade Federal do Estado do Rio de Janeiro (BR), Universidade Federal de São Paulo (BR)
Ministério da Saúde
Good health and well-being
Openalex Percentile: Top 6%
Neurogenetic and Muscular Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.